Camilla V. Simpson

Former Senior Vice President & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc.

Camilla V. Simpson

Camilla V. Simpson

Former Senior Vice President & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc.

Biography

Camilla V. Simpson holds the position of President & Managing Member at Rare Strategic LLC. She is also on the board of Spruce Biosciences, Inc., Aristea Therapeutics, Inc. and Dyve Biosciences, Inc. In the past Ms. Simpson held the position of Senior VP & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc. and Vice President-Regulatory Affairs for Shire Pharmaceuticals, Inc. Camilla V. Simpson received an undergraduate degree from Kingston University, an undergraduate degree from National University of Ireland Galway and a graduate degree from Birkbeck University of London.

Overview
RelSci Relationships

408

Birthday

1972

Age

49

Contact Data
Trying to get in touch with Camilla V. Simpson? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Camilla V. Simpson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Venture Partner at Pappas Capital LLC

Relationship likelihood: Strong

Senior Partner at Novo Ventures 1 A/S

Relationship likelihood: Strong

Co-Founder at Mirum Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Rapidscan Pharma Solutions, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Dakeyne Emms Gilmore Liberson Ltd.

Relationship likelihood: Strong

Founder, President & Chief Executive Officer at Aristea Therapeutics, Inc.

Relationship likelihood: Average

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Executive Vice President & Chief Financial Officer at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Executive Vice President, General Counsel & Secretary at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Chief Medical Officer & Executive Vice President at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Average

Paths to Camilla V. Simpson
Potential Connections via
Relationship Science
You
Camilla V. Simpson
Former Senior Vice President & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc.
Education

Minnesota Steel Industries LLC manufactures steel. It incorporated the commercially available technology in mining, concentrating, pellet plant, DRI and electric arc steelmaking on a single site, making it one of the lowest cost steel producers in the world. The company is headquartered in St. Paul, MN.

Birkbeck, University of London, is a public research university located in Bloomsbury, London.

Career History
Senior Vice President & Head-Product Portfolio Development
2014 - 2019

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Vice President-Regulatory Affairs
Prior

Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA

Boards & Committees
Director
2019 - Current

Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA.

Independent Director
2017 - Current

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The firm is initially developing its wholly-owned product candidate, tildacerfont, as the non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).The company was founded on November 13, 2014 and is headquartered in Daly City, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Camilla V. Simpson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Camilla V. Simpson's profile does not indicate a business or promotional relationship of any kind between RelSci and Camilla V. Simpson.